Get the Stockscreener App
4.83
9.52%
0.42
After Hours:
4.93
0.10
+2.07%
Nuvation Bio Inc stock is traded at $4.83, with a volume of 10.88M.
It is up +9.52% in the last 24 hours and up +9.52% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$4.41
Open:
$4.37
24h Volume:
10.88M
Relative Volume:
2.43
Market Cap:
$1.68B
Revenue:
$62.90M
Net Income/Loss:
$-204.63M
P/E Ratio:
-8.054
EPS:
-0.5997
Net Cash Flow:
$-181.78M
1W Performance:
+5.92%
1M Performance:
+9.52%
6M Performance:
-1.83%
1Y Performance:
+102.94%
1-Day Range:
$4.12
$4.85
1-Week Range:
$4.12
$4.85
52-Week Range:
$1.57
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.83 | 1.53B | 62.90M | -204.63M | -181.78M | -0.5997 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio's CEO and CFO line up four investor webcasts in May - Stock Titan
NUVB Stock Rallies As IBTROZI Drives Surprise Profit - StocksToTrade
Nuvation Bio Inc. 2026 Q1 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Nuvation Bio Inc. (NYSE:NUVB) Q1 2026 Earnings Call Transcript - Insider Monkey
Nuvation Bio Falls Short on Q1 2026: $0.01 EPS vs $0.01 Expected - AlphaStreet
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress By Investing.com - Investing.com Australia
Citizens reiterates Nuvation Bio stock rating on Ibtrozi launch progress - Investing.com
Nuvation Bio Q1 2026 Earnings Call Transcript - MarketBeat
Nuvation Bio Q1 Earnings Call Highlights - Yahoo Finance
Nuvation Bio Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Nuvation Bio Inc. (NUVB) lags Q1 earnings estimates - MSN
NUVB: Ibtrozi's first-line uptake and revenue growth accelerate, supported by strong financials - TradingView
Nuvation Bio (NUVB) Q1 2026 Earnings Transcript - The Globe and Mail
MSN Money - MSN
Earnings call transcript: Nuvation Bio Q1 2026 sees revenue beat, flat EPS - Investing.com
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates - Yahoo Finance
Nuvation Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvation Bio Q1 Swings to Profit, Revenue Rise - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Posts Q1 EPS $0.01, vs. FactSet Est of $0.03 Loss - marketscreener.com
Earnings Flash (NUVB) Nuvation Bio Inc. Reports Q1 Revenue $83.2M, Vs. FactSet Est of $65.7M - Moomoo
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Nuvation Bio (NUVB) swings to Q1 profit on $83M taletrectinib revenue - Stock Titan
Nuvation Bio Inc. (NUVB) reports next week: Wall Street expects earnings growth - MSN
Nuvation Bio earnings up next: Can IBTROZI launch momentum continue? By Investing.com - Investing.com South Africa
Nuvation Bio earnings up next: Can IBTROZI launch momentum continue? - Investing.com UK
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Are options traders betting on a big move in Nuvation Bio stock? - MSN
Earnings Preview: Nuvation Bio to Report Financial Results Post-market on May 04 - Moomoo
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Nuvation Bio gains global rights to brain cancer therapy from Daiichi Sankyo - MSN
H.C. Wainwright reiterates Nuvation Bio stock rating on NCCN addition - Investing.com UK
H.C. Wainwright reiterates Nuvation Bio stock rating on NCCN addition By Investing.com - Investing.com India
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - MSN
Down 24% in 4 weeks, here's why Nuvation Bio (NUVB) looks ripe for a turnaround - MSN
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers - Investing News Network
Nuvation Bio announces National Comprehensive Cancer Network® adds taletrectinib (Ibtrozi®) as recommended option - marketscreener.com
Nuvation Bio (NUVB) Projected to Post Earnings on Monday - MarketBeat
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers - PR Newswire
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):